Biotech Values

[Covid19freak]

MTCR up 21% ,company about to release Phase 2a interim data from their NASH program expected early october . What are the odds of positive outcome ? If its positive i think we could see a very nice jump here ...


New Presentation
https://investors.metacrine.com/static-files/fcad6a5f-fb5c-4a93-9e7f-344c4e1b216a


Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash

Exceeded enrollment target of 180 total patients Interim data from the first 60 patients expected early in the fourth quarter of 2021 Topline MET642 trial results from all patients are anticipated in the first half of 2022 SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc.